-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
<>/* Style Definitions */ span.
After injection of 8MW2311 into the body, it can stimulate the phosphorylation of the downstream transcription factor STAT5, and effectively stimulate the proliferation of killer T lymphocytes CD8+ T cells, thereby exerting its medicinal effect
Since its establishment in 2017, Maiwei Bio has built an innovative system starting from antibody drug target discovery and molecular discovery, covering the whole cycle of drug research and development such as druggability research, preclinical research, clinical research, and production transformation, to achieve integrated research and development, production.
These statements are inherently subject to considerable risk and uncertainty
These statements are not guarantees for future development and are subject to risks, uncertainties and other factors, some of which are beyond the control of the company and are difficult to predict
8MW2311 for injection is a polyethylene glycol conjugated human interleukin-2 immune agonist for the treatment of advanced malignant tumors
.
After injection of 8MW2311 into the body, it can stimulate the phosphorylation of the downstream transcription factor STAT5, and effectively stimulate the proliferation of killer T lymphocytes CD8+ T cells, thereby exerting its medicinal effect
About Maiwei Bio
Maiwei Bio (stock code: 688062) is an innovative biopharmaceutical company with a whole industry chain layout.
It has always adhered to the vision of "turning innovation from dream into reality", and practiced the mission of "exploring life and benefiting health".
Innovation, providing patients with innovative biological drugs with better efficacy and greater accessibility to meet the global unmet clinical needs
.
Since its establishment in 2017, Maiwei Bio has built an innovative system starting from antibody drug target discovery and molecular discovery, covering the whole cycle of drug research and development such as druggability research, preclinical research, clinical research, and production transformation, to achieve integrated research and development, production.
Forward-Looking Statements
Information published in this press release may contain certain forward-looking statements
.
These statements are inherently subject to considerable risk and uncertainty
These forward-looking statements are based on the Company's management's current beliefs, assumptions, expectations, estimates, projections and understanding of future events at the time the statements are made
.
These statements are not guarantees for future development and are subject to risks, uncertainties and other factors, some of which are beyond the control of the company and are difficult to predict
The Company, its directors and employee agents disclaim (a) any obligation to correct or update the forward-looking statements contained in this website; and (b) any responsibility
